PDCD1 and neoplasm: In our study, we demonstrated the effectiveness of SNS-101 in combination with a murine PD-1 immune checkpoint inhibitor (ICI) using the MC38 colon, MB49 bladder and MCA/1956 sarcoma syngeneic tumor models.